The global prevalence of LGMDs is estimated to range from 0.8 to 6.9 per 100,000 individuals, with CAPN3-related calpainopathy (LGMD2A/R1) emerging as the most common subtype, followed by DYSF-related LGMD (LGMDR2) [7,14,15]. This evidence concerns the gene CAPN3 and limb-girdle muscular dystrophy.